Firms
Theme

SYF

SYNCHRONY FINANCIAL · NYSE

News

11 latest

Zacks Investment Research

Synchrony (SYF) Upgraded to Buy: What Does It Mean for the Stock?

Synchrony (SYF) has been upgraded to a Zacks Rank #2 (Buy) rating, driven by upward trends in earnings estimates. The upgrade reflects improving business fundamentals, with analysts steadily raising estimates over the past three months. The stock is positioned in the top 20% of Zacks-covered stocks and may experience near-term price appreciation based on the correlation between earnings estimate revisions and stock performance.

Zacks Investment Research

SYF or FUTU: Which Is the Better Value Stock Right Now?

In a comparison of two Financial - Miscellaneous Services sector stocks, Synchrony (SYF) emerges as the superior value option for value investors. SYF holds a Zacks Rank of #2 (Buy) with a Value grade of A, featuring a lower forward P/E ratio of 7.84 and PEG ratio of 0.86.

Zacks Investment Research

Synchrony Q3 Earnings Beat Estimates on Improved Purchase Volume

Synchrony Financial (SYF) reported Q3 adjusted EPS of $2.68, beating estimates by 8.1% despite a 6.3% year-over-year decline. The company raised its 2026 EPS outlook to approximately $9.50 per share, driven by strong purchase volume growth of 8% to $49.7 billion and improved credit performance, though higher operating expenses and credit loss provisions partially offset gains.

Zacks Investment Research

Synchrony (SYF) Q3 Earnings Top Estimates

Synchrony reported Q3 2026 earnings of $2.68 per share, beating consensus estimates of $2.48 by 8.07%, but missed revenue expectations with $4.81 billion versus the estimated $4.96 billion. The stock has underperformed the S&P 500 by 23.4% year-to-date and carries a Zacks Rank #3 (Hold) rating. The Financial - Miscellaneous Services industry ranks in the bottom 31% of Zacks industries.

Zacks Investment Research

Can Higher Purchase Volumes Lift Synchrony Financial's Q3 Earnings?

Synchrony Financial (SYF) is expected to report Q3 2026 earnings on Oct. 20 with EPS forecasted at $2.48 (down 13.3% YoY) on $4.84B revenues (up 2.6% YoY). While purchase volumes and interest-earning assets are expected to grow, the company faces headwinds from higher employee and processing costs, nearly 10% RSA growth, and a declining net interest margin. The stock has a positive Earnings ESP of +5.87% and Zacks Rank #3, suggesting a likely earnings beat.

Zacks Investment Research

Is the Options Market Predicting a Spike in Synchrony Financial Stock?

Options traders are pricing in significant volatility for Synchrony Financial (SYF) ahead of December 18, 2026, with the $28.00 call showing high implied volatility. While analysts have modestly increased earnings estimates over the past 60 days, the stock holds a Zacks Rank #3 (Hold) rating. The elevated implied volatility may indicate traders are positioning for a major move, though it could also present opportunities for premium-selling strategies.

Zacks Investment Research

Synchrony (SYF) Expected to Beat Earnings Estimates: Should You Buy?

Synchrony (SYF) is positioned as a compelling earnings-beat candidate for its Q3 2026 results expected October 20. With a positive Earnings ESP of +5.87% and Zacks Rank #3, analysts expect the company to beat consensus EPS estimates of $2.48 per share, though earnings are projected to decline 13.3% year-over-year while revenues grow 2.6% to $4.84 billion. The company has beaten consensus estimates in 3 of the last 4 quarters.

Zacks Investment Research

Synchrony Deepens CareCredit's Veterinary Reach With Vetspire Tie-Up

Synchrony Financial is integrating CareCredit financing directly into Vetspire's AI-enabled practice management platform used by over 1,000 veterinary clinics. The partnership embeds financing options into the clinical workflow to improve treatment acceptance and efficiency. Health & Wellness purchase volume rose 2.1% year-over-year in Q2 2026, with growth driven by pet spending.

Zacks Investment Research

How Can Trust Shape Synchrony Financial's AI Shopping Opportunity?

Synchrony Financial's study reveals that trust, security, and fraud protection are more critical than convenience in driving consumer adoption of AI shopping agents. While 79% of consumers would allow AI to apply discounts and 74% to use loyalty rewards, only 54% would trust AI with purchases over $5,000. The company is developing tools to keep credit products, rewards, and offers visible when AI agents shop, positioning itself to benefit from the growing agentic commerce trend.

Mentions SYF

The Motley Fool

Synchrony: 3 Key Takeaways for Long-Term Investors

Synchrony raised its full-year earnings guidance to $9.50 per diluted share and is expanding into AI shopping channels and digital wallets through partnerships with OpenAI. The company is leveraging proprietary data analytics and underwriting tools to capture younger demographics (Gen Z and millennials) while maintaining strong purchase volumes near historic highs. Management emphasizes disciplined capital allocation focused on share buybacks and technology investments.

Zacks Investment Research

Moody's (MCO) Earnings Expected to Grow: Should You Buy?

Moody's is expected to report Q3 2026 earnings of $4.24 per share with 2.6% revenue growth, but a negative Earnings ESP of -2.32% suggests analysts have recently become bearish, making an earnings beat unlikely. In contrast, Synchrony shows a positive Earnings ESP of +2.69% with a Zacks Rank #3, indicating it is more likely to beat consensus estimates despite a 13.3% year-over-year EPS decline.

Headlines link to the publisher. Not investment advice.

Analysts

All ›

Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.

Community

7 days

No sentiment yet

Posts 24h
0
Replies 24h
0
Watchers
0

Board · $SYF · 0 threads

Sign in to post on $SYF

Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.

Cylvex is a financial simulation and community platform designed for educational and informational purposes only. Market data may be delayed. Nothing on this platform constitutes investment advice, financial advice, trading advice, or any other sort of advice. You should not treat any of the platform's content as such. Cylvex does not recommend that any financial instrument should be bought, sold, or held by you. Do conduct your own due diligence and consult your financial advisor before making any investment decisions. By using Cylvex, you acknowledge that you are using the platform at your own risk.

Terms · Privacy · Disclaimer · Methodology · Logos provided by Logo.dev